Therapeutic areas
Four areas, one medicine in each. A company our size has no business pretending otherwise.
Therapeutic area
Oncology
KRAS is mutated in roughly a quarter of all human cancers, and G12D is the most common variant of all — yet it has been among the hardest to drug.
BX-101 is an oral targeted degrader designed to remove mutant KRAS G12D protein rather than block it, with selectivity over wild-type KRAS. Removing the protein should also avoid the rebound signalling that limits inhibitors.
Program: BX-101 — Phase 1 dose escalation
Conditions in scope
- Pancreatic ductal adenocarcinoma
- Colorectal cancer
- Non-small cell lung cancer
Therapeutic area
Immunology & Inflammation
Around a third of people with Crohn's disease develop fibrostenotic complications, and no current therapy is designed for them.
BX-204 is an oral TL1A antagonist. TL1A sits upstream of both the inflammatory and the fibrotic arms of intestinal disease, which is why we selected it over the better-trodden cytokine targets — and why our trials stratify patients by intestinal TL1A expression.
Program: BX-204 — Phase 1
Conditions in scope
- Fibrostenotic Crohn's disease
- Ulcerative colitis (planned)
Therapeutic area
Neuroscience
ALS has a median survival of two to five years from diagnosis, and disease-modifying options remain very limited.
BX-308 is an intrathecally delivered antisense oligonucleotide against a genetically validated ALS target. Neurofilament light is built into the design from first-in-human onward, so we will know early whether we are affecting the disease process.
Program: BX-308 — IND-enabling studies
Conditions in scope
- Amyotrophic lateral sclerosis
- Frontotemporal dementia (discovery)
Therapeutic area
Cardiometabolic
Roughly one in five people has elevated lipoprotein(a), an independent, inherited and currently untreatable driver of cardiovascular risk.
BX-412 is a liver-directed siRNA that silences LPA transcription. Human genetics gives an unusually clean read on both direction and magnitude of effect here, which is exactly the kind of target a small company should be working on.
Program: BX-412 — Phase 1
Conditions in scope
- Elevated lipoprotein(a)
- Residual cardiovascular risk
The other half of the company
Alongside the medicines, Baxtra Surgical builds the imaging, robotics and biomaterials used in the operating room.